サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1659419

骨髄増殖性疾患治療薬の世界市場

Myeloproliferative Disorders Drugs

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
骨髄増殖性疾患治療薬の世界市場
出版日: 2025年02月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

骨髄増殖性疾患治療薬の世界市場は2030年までに129億米ドルに達する見込み

2024年に100億米ドルと推定される骨髄増殖性疾患治療薬の世界市場は、2030年には129億米ドルに達し、分析期間2024-2030年のCAGRは4.3%で成長すると予測されます。本レポートで分析したセグメントの1つであるPh+型慢性骨髄性白血病（CML）治療薬は、CAGR 3.7%を記録し、分析期間終了時には92億米ドルに達すると予測されます。骨髄増殖性腫瘍（MPN）治療薬セグメントは、分析期間中にCAGR 5.7%の成長が見込まれます。

米国市場は26億米ドル、中国はCAGR6.6%で成長すると予測

米国の骨髄増殖性疾患治療薬市場は2024年に26億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.6％を引きずる形で、2030年までに27億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と3.3％と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の骨髄増殖性疾患治療薬市場- 主要動向と促進要因のまとめ

骨髄増殖性疾患治療薬市場はどのように進化しているか？

骨髄増殖性疾患（MPD）治療薬市場は、これらの疾患の発生率の増加、治療選択肢の継続的な進歩、患者および医療従事者の意識の高まりにより、着実に拡大しています。MPDには、真性多血症、本態性血小板血症、骨髄線維症など、骨髄における血液細胞の過剰産生を特徴とする血液がん群が含まれます。これらの疾患は、血栓や出血の問題、急性白血病への進行など、さまざまな合併症を引き起こす可能性があります。治療の主な目標は、症状の管理、合併症のリスクの軽減、および疾患の進行を遅らせることです。現在の治療法には、細胞還元療法、JAK阻害剤、輸血などの支持療法があります。MPDの治療法が確立されていない現在、治療法はより的を絞った効果的な治療法へと進化しています。

骨髄増殖性疾患の薬剤開発の動向は？

MPDの薬剤開発は、疾患の進行に関与する特定の分子経路を阻害することに焦点を当てた標的療法へとシフトしています。ルキソリチニブなどのJAK阻害剤は、骨髄線維症やその他のMPDサブタイプの第一選択治療薬として広く受け入れられています。この分野における新たな動向としては、JAK阻害剤と他の新規薬剤を組み合わせて治療効果を高め、患者の生存期間を延長する併用療法の研究が挙げられます。さらに、分子診断学の進歩により、MPDによくみられるJAK2、CALR、MPLなどの遺伝子変異をより正確に特定できるようになり、個別化治療戦略が可能になりつつあります。市場はまた、疾患の進行に重要な役割を果たす骨髄微小環境をターゲットとした治療法の開発にもますます注力しています。

市場成長を牽引するセグメントは？

薬剤クラス別では、JAK阻害剤が骨髄線維症や真性多血症の管理において確立された役割を果たすため、市場を独占しています。第2世代のJAK阻害剤や他の経路を標的とする新規薬剤の開発により、このセグメントはさらに拡大すると予想されます。投与経路には経口剤と注射剤があり、使いやすさと患者のコンプライアンスから経口剤が好まれています。主な流通経路は病院薬局と専門薬局であり、後者はMPD治療の特殊性から脚光を浴びています。地理的には、北米が最大の市場シェアを占めているが、これはMPDの有病率が高いこと、ヘルスケアのインフラがしっかりしていること、革新的な治療法が早くから採用されていることなどが背景にあります。

骨髄増殖性疾患治療薬市場の成長を促進する要因は？

骨髄増殖性疾患治療薬市場の成長は、特に高齢化社会におけるこれらの疾患の有病率の増加、MPDの早期発見と正確な分類を促進する分子診断の進歩など、いくつかの要因によって牽引されています。JAK阻害剤のような標的治療薬の開発や、新たな治療法の組み合わせに関する継続的な研究により、治療環境が強化され、患者により効果的な選択肢が提供されています。遺伝子検査に支えられた個別化医療への注目の高まりも、よりオーダーメイドで効果的な治療戦略を可能にしています。さらに、新薬の臨床試験の拡大と規制当局の承認により、患者は最先端の治療法を利用できるようになり、市場の成長を促進しています。

セグメント

適応症：Ph+慢性骨髄性白血病（CML）、Ph-骨髄増殖性新生物（MPNs）

調査対象企業の例（全34件）

  • AbbVie, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Company Limited
  • CTI BioPharma Corporation
  • Incyte Corporation
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc.
  • Kymera Therapeutics
  • Merck & Co., Inc.
  • PharmaEssentia
  • Takeda Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22342

Global Myeloproliferative Disorders Drugs Market to Reach US$12.9 Billion by 2030

The global market for Myeloproliferative Disorders Drugs estimated at US$10.0 Billion in the year 2024, is expected to reach US$12.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic Myelogenous Leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Ph- Myeloproliferative Neoplasms (MPNs) Drugs segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 6.6% CAGR

The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Myeloproliferative Disorders Drugs Market - Key Trends and Drivers Summarized

How Is the Market for Myeloproliferative Disorders Drugs Evolving?

The market for Myeloproliferative Disorders (MPD) drugs is expanding steadily due to the increasing incidence of these conditions, ongoing advancements in treatment options, and growing awareness among both patients and healthcare professionals. MPD encompasses a group of blood cancers characterized by the excessive production of blood cells in the bone marrow, including polycythemia vera, essential thrombocythemia, and myelofibrosis. These disorders can lead to various complications such as blood clots, bleeding issues, and progression to acute leukemia. The primary goals of treatment include managing symptoms, reducing the risk of complications, and delaying disease progression. Current therapeutic options include cytoreductive therapies, JAK inhibitors, and supportive treatments like blood transfusions. With no known cure for MPD, the treatment landscape is evolving towards more targeted and effective management options.

What Are the Current Trends in Myeloproliferative Disorders Drug Development?

The drug development landscape for MPD is shifting towards targeted therapies, which focus on inhibiting specific molecular pathways involved in disease progression. JAK inhibitors, such as ruxolitinib, have gained widespread acceptance as the first-line treatment for myelofibrosis and other MPD subtypes. Emerging trends in this space include the exploration of combination therapies that pair JAK inhibitors with other novel agents to enhance treatment efficacy and extend patient survival. Additionally, advances in molecular diagnostics are allowing for more precise identification of genetic mutations, such as JAK2, CALR, and MPL, which are commonly associated with MPD, thereby enabling personalized treatment strategies. The market is also witnessing an increased focus on developing therapies that target the bone marrow microenvironment, which plays a critical role in disease progression.

Which Segments Are Driving Market Growth?

By drug class, JAK inhibitors dominate the market due to their established role in managing myelofibrosis and polycythemia vera. The development of second-generation JAK inhibitors and novel agents targeting other pathways is expected to further expand this segment. Routes of administration include oral and injectable, with oral medications preferred for their ease of use and patient compliance. Hospital pharmacies and specialty pharmacies are the primary distribution channels, with the latter gaining prominence due to the specialized nature of MPD treatments. Geographically, North America holds the largest market share, driven by a higher prevalence of MPD, robust healthcare infrastructure, and early adoption of innovative therapies.

What Factors Are Driving the Growth in the Myeloproliferative Disorders Drugs Market?

The growth in the Myeloproliferative Disorders drugs market is driven by several factors, including the increasing prevalence of these disorders, especially among aging populations, and advancements in molecular diagnostics that facilitate early detection and precise classification of MPD. The development of targeted therapies, such as JAK inhibitors, and ongoing research into new treatment combinations are enhancing the therapeutic landscape, offering patients more effective options. The rising focus on personalized medicine, supported by genetic testing, is also enabling more tailored and effective treatment strategies. Furthermore, the expansion of clinical trials and regulatory approvals for new drugs is providing patients with access to cutting-edge therapies, driving market growth.

SCOPE OF STUDY:

The report analyzes the Myeloproliferative Disorders Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Company Limited
  • CTI BioPharma Corporation
  • Incyte Corporation
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc.
  • Kymera Therapeutics
  • Merck & Co., Inc.
  • PharmaEssentia
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Myeloproliferative Disorders Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Advanced Therapies for Blood Cancers Spurs Growth in Myeloproliferative Disorders Drugs Market
    • Technological Advancements in Janus Kinase (JAK) Inhibitors Strengthen Business Case for Adoption
    • Growing Focus on Personalized Medicine and Mutation-Targeted Therapies Expands Addressable Market
    • Expansion of Myeloproliferative Disorders Drugs in Hematology-Oncology Practices Fuels Market Growth
    • Increasing Adoption of Combination Treatment Regimens Expands Market Opportunities
    • Technological Innovations in Epigenetic and Signal Transduction Inhibitors Propel Market Expansion
    • Rising Focus on Prolonging Disease-Free Survival and Managing Symptoms Drives Demand for Myeloproliferative Disorder Drugs
    • Growing Use of Myeloproliferative Disorder Drugs in Thrombosis Prevention and Symptom Control Expands Market Potential
    • Rising Adoption of Novel Agents in Advanced and Refractory Disease Expands Addressable Market
    • Technological Advancements in Cytokine Inhibitors and Molecularly Targeted Drugs Propel Market Growth
    • Increasing Focus on Reducing Treatment Toxicity and Enhancing Compliance Drives Adoption
    • Rising Demand for Myeloproliferative Disorder Drugs in Supportive and Palliative Care Strengthens Global Market
    • Expansion of Myeloproliferative Disorder Drugs in Community-Based and Hospital-Based Oncology Settings Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Myeloproliferative Disorders Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • JAPAN
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • CHINA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • EUROPE
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • FRANCE
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • GERMANY
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • INDIA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • AFRICA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030

IV. COMPETITION